Literature DB >> 10489622

Gliomas.

V P Collins1.   

Abstract

Gliomas are thought to arise from the glial cells of brain tissue. The spectrum of tumours varies with age, implying that cells in a particular state of development are a prerequisite for the occurrence of some tumour types. Premalignant states are not recognized, so we know little about the earliest events in oncogenesis. However, progression of gliomas has been examined by studying large series of tumours of different malignancy grades and by following cases where the tumour is of low malignancy grade at first diagnosis and recurs later as a tumour of higher malignancy grade. When considering premalignant states we can only extrapolate from our knowledge of progression from the least to the most malignant tumour forms. The best studied variants are the astrocytic tumours. There are no consistent genetic aberrations known to characterize the most benign variant of astrocytoma, the pilocytic astrocytoma (malignancy grade I), which occurs mainly in children. Astrocytomas (malignancy grade II) show loss of alleles at 13q, 17p and 22q and occur mainly in early middle age. Loss of one TP53 allele (17p) is associated with mutation of the remaining allele. Loss of one RB1 allele is not. Anaplastic astrocytomas (malignancy grade III) have in approximately 50% of cases aberrations of genes coding for proteins involved in the control of entry into the S phase of the cell cycle, as well as other genetic defects affecting unknown genes. The greatest number of genetic abnormalities is seen in glioblastomas (malignancy grade IV), which have a peak incidence in late middle age. Around 80% of glioblastomas can be shown to have genetic alterations resulting in aberrant control of progression from G1 to the S phase of the cell cycle, and many show amplification of growth factor receptor genes as well as other abnormalities. The bewildering number of genetic anomalies becomes intelligible as we discover that different components of the same cellular control mechanisms are being targeted in individual tumours resulting in a similar phenotype.

Entities:  

Mesh:

Year:  1998        PMID: 10489622

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  10 in total

1.  Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta/c-Src pathways in glioblastoma cells.

Authors:  Samson Amos; Patrick M Martin; Gregory A Polar; Sarah J Parsons; Isa M Hussaini
Journal:  J Biol Chem       Date:  2004-12-23       Impact factor: 5.157

2.  Biologic tumor behavior in pilocytic astrocytomas.

Authors:  Muhittin Belirgen; Su Gulsun Berrak; Hilâl Ozdag; Suheyla Uyar Bozkurt; Emel Eksioglu-Demiralp; M Memet Ozek
Journal:  Childs Nerv Syst       Date:  2012-01-14       Impact factor: 1.475

3.  Integrated Biophysical Modeling and Image Analysis: Application to Neuro-Oncology.

Authors:  Andreas Mang; Spyridon Bakas; Shashank Subramanian; Christos Davatzikos; George Biros
Journal:  Annu Rev Biomed Eng       Date:  2020-06-04       Impact factor: 9.590

4.  MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.

Authors:  Jing Han; Qianxue Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  GLISTR: glioma image segmentation and registration.

Authors:  Ali Gooya; Kilian M Pohl; Michel Bilello; Luigi Cirillo; George Biros; Elias R Melhem; Christos Davatzikos
Journal:  IEEE Trans Med Imaging       Date:  2012-08-13       Impact factor: 10.048

6.  Rig is a novel Ras-related protein and potential neural tumor suppressor.

Authors:  Chad A Ellis; Michele D Vos; Heather Howell; Teresa Vallecorsa; Daniel W Fults; Geoffrey J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-09       Impact factor: 11.205

7.  Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.

Authors:  Michael S Enslow; Lauren V Zollinger; Kathryn A Morton; Regan I Butterfield; Dan J Kadrmas; Paul E Christian; Kenneth M Boucher; Marta E Heilbrun; Randy L Jensen; John M Hoffman
Journal:  Clin Nucl Med       Date:  2012-09       Impact factor: 7.794

8.  The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Authors:  Sarah Ball; Chenglong Li; Pui-Kai Li; Jiayuh Lin
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

Review 9.  Role of Circular RNA in Brain Tumor Development.

Authors:  Swalih P Ahmed; Javier S Castresana; Mehdi H Shahi
Journal:  Cells       Date:  2022-07-06       Impact factor: 7.666

10.  Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use.

Authors:  Lennart Hardell; Michael Carlberg; Fredrik Söderqvist; Kjell Hansson Mild
Journal:  Int J Oncol       Date:  2013-09-24       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.